| Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. | |
| | |
MedLine Citation:
|
PMID: 20950401 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Abnormal iron regulation in patients with thalassaemia intermedia may lead to iron overload even in the absence of transfusions. There are limited data on iron chelator use in patients with thalassaemia intermedia and no guidelines exist for the management of iron overload. We present data from 11 patients with thalassaemia intermedia treated with deferasirox (Exjade(®) , 10-20 mg/kg/d) for 24 months. Liver iron concentration and serum ferritin levels significantly decreased over the first 12 months (P = 0·005) and continued to decrease over the remainder of the study (P = 0·005). This small-scale study indicated that deferasirox may be suitable for controlling iron levels in patients with thalassaemia intermedia. |
| | |
Authors:
|
Vassilis Ladis; Helen Berdousi; Efstathios Gotsis; Antonis Kattamis |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-18 |
Journal Detail:
|
Title: British journal of haematology Volume: 151 ISSN: 1365-2141 ISO Abbreviation: Br. J. Haematol. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-12 Completed Date: 2011-01-03 Revised Date: 2011-01-07 |
Medline Journal Info:
|
Nlm Unique ID: 0372544 Medline TA: Br J Haematol Country: England |
Other Details:
|
Languages: eng Pagination: 504-8 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
First Department of Paediatrics, Athens University, Thalassaemia Unit, Aghia Sofia Children's Hospital Encephalos-Euromedica Laboratories, Rizariou 3, Halandri, Athens Greece. thalas@paidon-agiasofia.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Benzoic Acids / adverse effects, therapeutic use* Female Ferritins / blood Humans Iron / metabolism Iron Chelating Agents / adverse effects, therapeutic use* Iron Overload / diagnosis, drug therapy*, etiology, metabolism Liver / metabolism Magnetic Resonance Imaging Male Treatment Outcome Triazoles / adverse effects, therapeutic use* Young Adult beta-Thalassemia / complications*, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Benzoic Acids; 0/Iron Chelating Agents; 0/Triazoles; 0/deferasirox; 7439-89-6/Iron; 9007-73-2/Ferritins |
| Comments/Corrections | |
Erratum In:
|
Br J Haematol. 2011 Jan;152(1):124 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Significance levels in genome-wide interaction analysis (GWIA).
Next Document: Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia ver...